Ksenak Stephen Michael
Known title: Sr. MD & General CounselCIK: 0001527850
Ksenak Stephen Michael's purchase track record
Ksenak Stephen Michael has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/7/2024 | OSG | $55K | +10.5% | +10.2% | +16.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| OSG | ▼ Sell | Other | 129,146 | $0 | 9/29/2025 | View on chart |
| OSG | ▼ Sell | Tax Withholding | 43,522 | $423K | 9/29/2025 | View on chart |
| OSG | ▲ Buy | Option Exercise | 4,726 | $0 | 3/13/2025 | View on chart |
| OSG | ▼ Sell | Tax Withholding | 1,703 | $14K | 3/13/2025 | View on chart |
| OSG | ▲ Buy | Option Exercise | 1,967 | $0 | 3/6/2025 | View on chart |
| OSG | ▼ Sell | Tax Withholding | 1,967 | $18K | 3/6/2025 | View on chart |
| OSG | ▲ Buy | Option Exercise | 400 | — | 3/3/2025 | View on chart |
| OSG | ▼ Sell | Tax Withholding | 400 | $4K | 3/3/2025 | View on chart |
| OSG | ▼ Sell | Tax Withholding | 582 | $6K | 2/28/2025 | View on chart |
| OSG | ▲ Buy | Option Exercise | 582 | — | 2/28/2025 | View on chart |
| OSG | ▲ Buy | Open Market | 5,000 | $55K | 8/7/2024 | View on chart |
| OSG | ▲ Buy | Option Exercise | 218 | $0 | 3/8/2024 | View on chart |
| OSG | ▼ Sell | Tax Withholding | 218 | $3K | 3/8/2024 | View on chart |
| OSG | ▲ Buy | Option Exercise | 163 | $0 | 3/3/2024 | View on chart |
| OSG | ▼ Sell | Tax Withholding | 163 | $3K | 3/3/2024 | View on chart |
| OSG | ▲ Buy | Option Exercise | 178 | $0 | 2/28/2024 | View on chart |
| OSG | ▼ Sell | Tax Withholding | 178 | $3K | 2/28/2024 | View on chart |
| OSG | ▼ Sell | Tax Withholding | 1,861 | $30K | 2/21/2024 | View on chart |
| OSG | ▲ Buy | Option Exercise | 1,861 | $0 | 2/21/2024 | View on chart |
| OSG | ▲ Buy | Option Exercise | 282 | $0 | 3/8/2023 | View on chart |
| OSG | ▲ Buy | Option Exercise | 282 | $5K | 3/8/2023 | View on chart |
| OSG | ▲ Buy | Option Exercise | 178 | $0 | 2/28/2023 | View on chart |
| OSG | ▲ Buy | Option Exercise | 178 | $3K | 2/28/2023 | View on chart |
| OSG | ▲ Buy | Option Exercise | 36,351 | $0 | 2/22/2023 | View on chart |
| OSG | ▼ Sell | Tax Withholding | 18,606 | $302K | 2/22/2023 | View on chart |
| OSG | ▲ Buy | Option Exercise | 2,778 | $0 | 1/2/2023 | View on chart |
| OSG | ▲ Buy | Option Exercise | 1,579 | $28K | 1/2/2023 | View on chart |
| OSG | ▲ Buy | Option Exercise | 6,177 | $0 | 3/8/2022 | View on chart |
| OSG | ▼ Sell | Tax Withholding | 3,153 | $41K | 3/8/2022 | View on chart |
| OSG | ▲ Buy | Option Exercise | 19,124 | $0 | 2/24/2022 | View on chart |
| OSG | ▼ Sell | Tax Withholding | 9,743 | $140K | 2/24/2022 | View on chart |
| OSG | ▲ Buy | Option Exercise | 4,965 | $0 | 1/2/2022 | View on chart |
| OSG | ▼ Sell | Tax Withholding | 2,823 | $45K | 1/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
E&S MGA Pivix Launches Assault & Battery Program
E&S MGA Pivix has announced a new assault and battery program. The launch could broaden the market for specialty insurance products, potentially affecting OSG’s competitive landscape. OSG is currently trading near its 11‑touch support level, and the new program may influence demand for specialty coverage. Investors may watch how the market responds to the expanded product offering.
E&S MGA Pivix Launches Assault & Battery Program. E&S MGA Pivix has announced a new assault and battery program. The launch could broaden the market for specialty insurance products, potentially affecting OSG’s competitive landscape. OSG is currently trading near its 11‑touch support level, and the new program may influence demand for specialty coverage. Investors may watch how the market responds to the expanded product offering.